Searchable abstracts of presentations at key conferences in endocrinology

ea0038p194 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Differences between men and women in markers of dietary fatty acid oxidation

McNeil Catriona , Pramfalk Camilla , Pavlides Michael , Karpe Fredrik , Hodson Leanne

Men have a higher prevalence and risk of non-alcoholic fatty liver disease (NAFLD) than age-matched women and this may, in part, be related to differences in fatty acid oxidation. Fasting and postprandial fatty acid oxidation was investigated in 11 healthy men and 11 healthy women matched for age (46±2 years vs 46±2 years (mean±S.E.M.)), BMI (28.0±1 vs 27.0±1 kg/m2) and liver fat content (3.4±0.9 vs 3.9±0.7%) measure...

ea0038p195 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Establishing human liver cell models to investigate the effects of exogenous metabolic substrates on fatty acid partitioning

Green Charlotte , McNeil Catriona , Morten Karl , Hodson Leanne

Hepatic steatosis, accumulation of intracellular triglyceride (TG) (>5% of hepatic tissue), is the prerequisite for the development of non-alcoholic fatty liver disease (NAFLD). NAFLD represents a spectrum of liver diseases and is associated with obesity and obesity-related metabolic diseases such as type 2 diabetes and cardiovascular disease. Steatosis occurs due to an imbalance between fatty acid input and removal (fatty acid partitioning) which can be affected by geneti...

ea0049gp69 | Developmental & Protein Endocrinology | ECE2017

5β-reductase (AKR1D1) is a potent regulator of carbohydrate and lipid metabolism and inflammation in human liver

Nikolaou Nikolaos , Gathercole Laura , Green Charlotte , McNeil Catriona , Arlt Wiebke , Hodson Leanne , Tomlinson Jeremy

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic disease. 5β-reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid hormones and catalyzes a fundamental step in bile acid synthesis. Steroid hormones, including glucocorticoids, as well as bile acids are established regulators of metabolic phenotype. We hypothesized that AKR1D1 plays a crucial regulatory role in hepatic metabolic homeostasis. Genetic manipulatio...

ea0044oc5.5 | Diabetes Mellitus and Metabolism | SFEBES2016

5β-reductase (AKR1D1) is a potent regulator of carbohydrate and lipid metabolism in human and rodent liver

Nikolaou Nikolaos , Gathercole Laura , Green Charlotte , McNeil Catriona , Hodson Leanne , Tomlinson Jeremy

Non-alcoholic fatty liver disease is the hepatic manifestation of metabolic disease. 5β-reductase (AKR1D1) is highly expressed in human and rodent liver where it inactivates steroid hormones and catalyzes a fundamental step in bile acid synthesis. Steroid hormones, including glucocorticoids, as well as bile acids are established regulators of metabolic phenotype. We have hypothesized that AKR1D1 plays a crucial regulatory role in hepatic metabolic homeostasis.<p class...

ea0050p318 | Obesity and Metabolism | SFEBES2017

5β-reductase (AKR1D1) is a potent regulator of carbohydrate and lipid metabolism and inflammation in human liver

Nikolaou Nikolaos , Gathercole Laura , Althari Sara , Green Charlotte , McNeil Catriona , Hughes Beverly , Arlt Wiebke , Hodson Leanne , Tomlinson Jeremy

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic disease. Steroid hormones and bile acids are established regulators of metabolic phenotype. 5β-reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid hormones and catalyzes a fundamental step in bile acid synthesis. We hypothesized that AKR1D1 plays a key role in hepatic metabolic homeostasis. Genetic manipulation of AKR1D1 ...

ea0050p318 | Obesity and Metabolism | SFEBES2017

5β-reductase (AKR1D1) is a potent regulator of carbohydrate and lipid metabolism and inflammation in human liver

Nikolaou Nikolaos , Gathercole Laura , Althari Sara , Green Charlotte , McNeil Catriona , Hughes Beverly , Arlt Wiebke , Hodson Leanne , Tomlinson Jeremy

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic disease. Steroid hormones and bile acids are established regulators of metabolic phenotype. 5β-reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid hormones and catalyzes a fundamental step in bile acid synthesis. We hypothesized that AKR1D1 plays a key role in hepatic metabolic homeostasis. Genetic manipulation of AKR1D1 ...

ea0059oc3.6 | Obesity &amp; diabetes | SFEBES2018

5β-reductase (AKR1D1) is a potent regulator of hepatic insulin sensitivity, carbohydrate and lipid metabolism in vitro and in vivo

Nikolaou Nikolaos , Gathercole Laura , Marchand Lea , Althari Sara , Green Charlotte , McNeil Catriona , Harris Shelley , van de Bunt Martijn , Arlt Wiebke , Hodson Leanne , Tomlinson Jeremy

Steroid hormones and BAs are established regulators of metabolic phenotype. 5β-reductase (AKR1D1) is highly expressed in the liver where it inactivates steroid hormones and catalyses a fundamental step in bile acid (BA) synthesis. We have hypothesised that AKR1D1 plays a crucial regulatory role in hepatic metabolic homeostasis. Genetic manipulation of AKR1D1 was performed in human liver HepG2 and Huh7 cells. Expression changes were confirmed by qPCR and western blotting, ...

ea0056oc6.1 | Genetic and environmental determinants of obesity and insulin resistance | ECE2018

5β-reductase (AKR1D1) is a potent regulator of hepatic insulin sensitivity, carbohydrate and lipid metabolism in vitro and in vivo

Nikolaou Nikolaos , Gathercole Laura , Marchand Lea , Althari Sara , Green Charlotte , McNeil Catriona , Harris Shelley , van de Bunt Martijn , Arlt Wiebke , Hodson Leanne , Tomlinson Jeremy

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic disease. 5β-reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid hormones and, in parallel, catalyzes a fundamental step in bile acid synthesis. Steroid hormones, including glucocorticoids, as well as bile acids (BAs) are established regulators of metabolic phenotype. We have hypothesized that AKR1D1 plays a crucial regulatory role in hepatic metabolic homeost...

ea0067o30 | Oral Presentations | EYES2019

AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease

Nikolaou Nikolaos , Gathercole Laura L , Marchand Lea , Althari Sara , Dempster Niall J , Green Charlotte J , van de Bunt Martijn , McNeil Catriona , Arvaniti Anastasia , Hughes Beverly A , Sgromo Bruno , Gillies Richard S , Ryan John , Arlt Wiebke , Hodson Leanne , Tomlinson Jeremy W

Objective: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. Steroid hormones and bile acids are potent regulators of hepatic carbohydrate and lipid metabolism. Steroid 5β-reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid hormones and catalyzes a fundamental step in bile acid synthesis.Methods: Human liver biopsies were obtained from 34 obese patients and AKR1D1 mRNA expres...